| 2025-05-05 | -1.36 % |
|
| 2025-05-02 | +1.13 % |
|
| 2025-05-01 | -1.97 % |
- Pfizer Inc. (PFE) stock fell by -1.97% despite better-than-expected quarterly earnings because its revenue of $13.72 billion missed analysts' estimates of $14.43 billion, indicating a decline in sales, and the overall market sentiment reflected cautiousness from investors.
- Pfizer (PFE) stock fell by 1.97% amid concerns over potential pharmaceutical tariffs being discussed by the Trump administration, which may affect the drug industry's manufacturing decisions and investment plans, leading to uncertainty and volatility in the market.
- Pfizer Inc.'s stock (PFE) experienced a -1.97% decline following a mixed earnings report where, despite better-than-expected earnings per share (EPS), the company's quarterly revenue fell short of analyst estimates, raising concerns about its financial performance.
- Pfizer (PFE) stock fell by 1.97% due to analysts favoring vTv Therapeutics over Pfizer based on stronger growth potential and higher price targets, reflecting a more optimistic outlook for vTv Therapeutics in comparison to Pfizer's performance.
- Pfizer (PFE) stock fell by 1.97% following the announcement that its partner Arvinas, Inc. would discontinue the development of vepdegestrant, an oral treatment for HR-positive breast cancer, which led to significant investor disappointment and concerns over the viability of their clinical progress and commercial opportunities.
|
| 2025-04-30 | +2.61 % |
- Pfizer (PFE) stock rose 2.61% amid high trading volume, likely driven by investor interest in the pharmaceutical company's consistent performance in developing medications and vaccines, including those for COVID-19 and other therapeutic areas.
- Pfizer (PFE) stock rose by 2.61% after the company reported better-than-expected quarterly earnings, with an EPS of $0.92, exceeding analysts' estimates of $0.67, which boosted investor confidence despite a slight decline in revenue compared to the previous year.
- Pfizer (PFE) stock rose by 2.61% last night, primarily due to recent research suggesting a connection between the Pfizer vaccine and increased risks of mortality compared to a competing vaccine, which is causing analysts to reevaluate the company’s future prospects and market position.
- The article discusses a recent 2.61% increase in Pfizer (PFE) stock; however, it primarily focuses on Representative Robert Bresnahan Jr.'s stock trades, including his sale of Mastercard shares, with limited connection to Pfizer's stock performance likely attributed to broader market movements or positive developments surrounding the company's products or financial outlook.
|
| 2025-04-29 | +3.21 % |
|
| 2025-04-28 | +0.57 % |
|
| 2025-04-25 | +0.61 % |
- Pfizer (PFE) stock rose 0.61% following the announcement of a class action lawsuit against Cerevel Therapeutics and Bain Capital, suggesting market optimism around the potential implications of the lawsuit or related developments in the sector.
- Pfizer (PFE) stock was up 0.61% likely due to positive market sentiment and developments in related biotechnology sectors, exemplified by Cogent Biosciences' presentation of promising preclinical data at the AACR 2025 Annual Meeting, which highlights advances in precision therapies that could influence investor confidence in biotech stocks, including Pfizer.
- Pfizer (PFE) stock increased by 0.61% due to its strong market presence as a major player among pharmaceutical stocks, which are currently experiencing heightened trading volumes and investor interest, likely driven by factors such as ongoing developments in their product pipelines and overall positive market sentiment in the pharmaceutical sector.
- Pfizer (PFE) stock rose by 0.61% following analysts at Cantor Fitzgerald predicting a FY2025 earnings per share of $2.99, which is above the consensus estimate of $2.95, as well as positive performance in prior earnings reports that surpassed expectations.
- Pfizer's (PFE) stock rose by 0.61% likely due to positive developments in biopharmaceutical research, specifically relating to collaborations and innovations presented by Nurix Therapeutics at the AACR Annual Meeting, including the efficacy of degraders in targeting difficult cancer mutations and CNS involvement, which could enhance treatment options.
|
| 2025-04-24 | +1.74 % |
|
| 2025-04-23 | -0.62 % |
|
| 2025-04-22 | +2.22 % |
|
| 2025-04-21 | -0.45 % |
- The article primarily discusses the comparison between Sangamo Therapeutics and Vericel, emphasizing their financial metrics and investment potential, and does not provide specific reasons for the decline of Pfizer (PFE) stock by -0.45%. The drop in Pfizer's stock could be attributed to various market conditions, investor sentiment, or broader industry trends that are not detailed in the article.
- Pfizer (PFE) stock saw a decline of 0.45% due to its association with Cerevel Therapeutics, which is facing a class action lawsuit alleging securities law violations related to insider trading and misleading stock offering practices.
- Pfizer (PFE) stock saw a decrease of 0.45%, likely influenced by competitive advancements from Ascentage Pharma, which received significant recognition for its innovative cancer treatments in China, potentially impacting investor sentiment towards Pfizer.
- Pfizer (PFE) stock fell by 0.45% due to expectations of lower earnings per share and quarterly revenue in its upcoming Q1 2025 earnings report, which forecasts a decline from the previous year's figures.
- The article discusses the impressive fundraising records achieved by President Trump during his second inauguration, revealing that various prominent companies, including Pfizer (PFE), were significant contributors. Pfizer's stock may have experienced a decline of 0.45% due to broader market uncertainties stemming from tariff implications that could adversely impact many businesses' supply chains and stock prices.
|
| 2025-04-17 | +0.45 % |
- The article discusses how Eli Lilly's stock rose following positive Phase 3 trial results for orforglipron, a new oral diabetes and weight loss medication that could compete with Ozempic, while Pfizer's stock increased slightly by 0.45% as the overall market anticipates developments in the diabetes drug sector. Pfizer's stock likely benefited from the market's excitement about new diabetes treatments, despite its own challenges with danuglipron.
- Pfizer (PFE) stock rose by 0.45%, attributed to overall investor interest in pharmaceutical stocks, driven by expectations of advancements in medical research and the companies' ability to navigate regulatory challenges.
- Pfizer (PFE) stock rose by 0.45% following Eli Lilly's announcement of promising clinical trial results for its oral diabetes medication, which has triggered concerns about competition in the weight loss treatment market for existing GLP-1 drugs, potentially benefiting Pfizer's stock as investors reassess its market position amidst ongoing drug development challenges.
- Pfizer (PFE) stock increased by 0.45% following Ligand Pharmaceuticals' announcement of a merger with Channel Therapeutics, which includes the commercialization of ZELSUVMI™, the first FDA-approved home treatment for molluscum contagiosum, highlighting the potential for growth in their biopharmaceutical portfolio.
- Pfizer (PFE) stock rose 0.45% following Eli Lilly's successful trial results for its oral weight-loss drug, orforglipron, which positioned Lilly as a frontrunner in the obesity drug market and emphasized the demand for oral medications over injectables, potentially leading Pfizer to seek acquisitions to remain competitive after abandoning its own weight-loss pill due to safety concerns.
|
| 2025-04-16 | -1.78 % |
|
| 2025-04-15 | +1.45 % |
- Pfizer (PFE) stock rose 1.45% despite recent setbacks in drug development, particularly the discontinuation of danuglipron for weight management, likely due to broader market trends or investor confidence in other aspects of the company's pipeline.
- Pfizer's (PFE) stock rose 1.45% amidst allegations against Icon PLC of misleading investors about its performance, which included claims that Icon's largest customers, including Pfizer, intended to diversify their business away from the company, negatively impacting Icon's demand.
The increase in Pfizer's stock may be attributed to market reactions following the news regarding Icon, suggesting that investors are reassessing their perception of Pfizer's business relationships and stability amidst these unfolding circumstances.
- Pfizer (PFE) stock rose by 1.45% recently due to the company's competitors, such as Novo Nordisk, facing setbacks with their own products, which could strengthen Pfizer's market position in the pharmaceutical sector.
- Pfizer (PFE) stock rose 1.45% likely due to positive market sentiment following the appointment of Dr. Leonardo Viana Nicacio as Chief Medical Officer at Protara Therapeutics, a company with potential therapies that may benefit from Pfizer’s previous acquisition of Seagen, where Nicacio had a significant role in oncology drug development.
|
| 2025-04-14 | +0.96 % |
- Pfizer (PFE) stock rose 0.96% as part of a broader rally in US and international markets, driven by positive investor sentiment following the White House's decision to exempt smartphones and computers from tariffs, which alleviated some market uncertainties.
- Pfizer (PFE) stock rose 0.96% last night potentially due to overall market positivity, despite the company's recent setback in halting the development of a weight-loss pill after safety concerns.
- The article discusses Pfizer Inc. (NYSE:PFE), noting that its stock rose by 0.96% recently, amidst broader market commentary by Jim Cramer regarding tariffs and inflation. Pfizer's stock increase may be attributed to positive sentiment around its potential in the biopharmaceutical sector, despite concerns about government taxation and tariffs affecting drug companies, which could impact stock prices negatively in the future.
- Pfizer (PFE) stock increased by 0.96% despite the company announcing the termination of its daily weight-loss pill development due to a liver injury in a trial, likely because investors remain optimistic about other ongoing projects and the overall market's positive response to weight-loss drug developments.
- Pfizer (PFE) stock rose 0.96% likely due to investor sentiment improved by the news of a class action lawsuit involving Cerevel Therapeutics, in which Pfizer is implicated, suggesting potential legal developments that could affect stock valuations positively.
|
| 2025-04-11 | +1.48 % |
|
| 2025-04-10 | -4 % |
|
| 2025-04-09 | +2.98 % |
- Pfizer (PFE) stock rose by 2.98% despite broader market volatility and increased tariffs, likely due to investor optimism or resilience in the pharmaceutical sector amidst concerns affecting other industries.
- Pfizer (PFE) stock rose by 2.98% despite a target price downgrade by UBS Group amid various neutral ratings from other analysts, likely influenced by the company's strong quarterly earnings and positive institutional investments.
- Pfizer (PFE) stock rose by 2.98% due to positive market sentiment attributed to expectations of stabilization in inflation and interest rates, alongside enhancements in pipeline collaborations, especially related to key partnerships with companies like Arvinas, which have promising therapeutic developments.
- The article discusses a significant surge in U.S. stock markets, including a 2.98% increase in Pfizer (PFE) stock, following President Trump's decision to pause tariffs against most other nations, which eased investor concerns and prompted optimism in the market.
Pfizer's stock likely went up due to the broader market rally resulting from Trump's tariff pause, which alleviated fears of escalating trade tensions and the potential economic fallout that could negatively impact the pharmaceutical sector.
- Pfizer (PFE) stock rose by 2.98% as it was among the pharmaceutical stocks experiencing notable trading volumes, possibly influenced by investor interest in the overall sector's potential growth from developments in drug approvals and healthcare policies.
|
| 2025-04-08 | -3.49 % |
|
| 2025-04-07 | -1.48 % |
|
| 2025-04-04 | -5.43 % |
|
| 2025-04-03 | -1.66 % |
- The article discusses Pfizer (PFE) stock's recent decline of 1.66%, attributed to broader market trends and investor sentiment impacting pharmaceutical companies post-pandemic as vaccine demand stabilizes.
- The article discusses the transformative role of cloud computing in business, highlighting common mistakes companies make in their cloud strategies, which can lead to costly errors, while it is unrelated to Pfizer's (PFE) stock decline of -1.66%.
Pfizer's stock may have gone down due to various market factors such as investor sentiment, financial performance, or concerns over future drug pipeline developments, though specific reasons for the decline were not provided in the article.
- The article discusses a report on a community cohort study revealing that human metapneumovirus (hMPV) causes a significant incidence of respiratory illness, particularly during winter months and among young children, which can disrupt daily activities.
As for the Pfizer (PFE) stock decline of -1.66%, the article does not provide specific reasons related to Pfizer's business or market activities to explain the drop. Stock fluctuations can be influenced by various factors including market sentiment, investor reactions, economic indicators, or company-specific news, which are not detailed in the provided text.
|
| 2025-04-02 | +0.65 % |
|
| 2025-04-01 | -3.16 % |
|
| 2025-03-31 | +0.52 % |
|
| 2025-03-28 | +0.8 % |
|
| 2025-03-27 | -0.79 % |
|
| 2025-03-25 | -2.26 % |
|
| 2025-03-24 | -0.53 % |
|
| 2025-03-21 | +0.34 % |
|
| 2025-03-20 | -0.08 % |
|
| 2025-03-19 | -0.38 % |
|
| 2025-03-18 | +1 % |
|
| 2025-03-14 | +0.47 % |
- Pfizer (PFE) stock rose 0.47% following a reissued "buy" rating from Guggenheim and strong quarterly earnings that exceeded analysts' expectations, indicating positive investor sentiment despite mixed ratings from other brokerages.
- Pfizer (PFE) stock is showing signs of recovery, recently increasing by 0.47%, as the company takes strategic steps, including acquisitions to enhance profitability and growth, amidst broader market volatility that has led investors to seek safer investments in the healthcare sector.
The stock's rise can be attributed to its potential value following previous corrections, solid profit margins, and resilience during downturns, despite ongoing concerns about its financial stability.
- The article discusses Nurix Therapeutics, Inc. granting stock options and restricted stock unit awards to new employees as part of its 2024 Equity Inducement Plan. Pfizer's stock (PFE) may have risen by 0.47% due to its collaboration with Nurix, which enhances its drug discovery pipeline, potentially leading to future growth in innovative treatments.
|
| 2025-03-12 | -1.08 % |
- Pfizer (PFE) stock experienced a decline of 1.08% last night, which may be influenced by broader market trends or specific developments within the company or industry that weren't detailed in the article.
- The article primarily discusses recent stock trading activity involving Arch Capital Group, particularly a purchase by Representative Jefferson Shreve, while Pfizer (PFE) stock saw a decline of -1.08%. Pfizer's stock likely went down due to broader market trends or company-specific news that could be influencing investor sentiment, although the article does not provide specific reasons for the decline in Pfizer's stock.
- The article mentions that Pfizer (PFE) stock recently declined by 1.08%, but it primarily discusses a stock purchase made by Representative Jefferson Shreve in General Electric, not providing specific reasons for Pfizer's stock decline.
Pfizer's stock may be down due to broader market trends, negative investor sentiment, or company-specific news, but the article does not specify the exact causes for this drop.
- The article discusses a recent purchase of Prologis, Inc. stock by Representative Jefferson Shreve, but it also mentions that Pfizer (PFE) stock was down by 1.08% last night, although the reason for the drop is not addressed within the article.
- Pfizer Inc. (PFE) stock fell by -1.08% partly in response to analysts downgrading their ratings and price targets for the company amid ongoing market fluctuations and uncertainties regarding the pharmaceutical sector.
|
| 2025-03-11 | -2.44 % |
|
| 2025-03-07 | +1.87 % |
|
| 2025-03-06 | +1.16 % |
|
| 2025-03-05 | +0.74 % |
|
| 2025-02-27 | -1.21 % |
|
| 2025-02-26 | -1.2 % |
|
| 2025-02-25 | +0.34 % |
|
| 2025-02-24 | +1.33 % |
|
| 2025-02-19 | +1.29 % |
|
| 2025-02-14 | -0.43 % |
|
| 2025-02-13 | +0.67 % |
|
| 2025-02-12 | -0.24 % |
|
| 2025-02-11 | -1.31 % |
|
| 2025-02-10 | +0.51 % |
|
| 2025-02-07 | -0.35 % |
|
| 2025-02-06 | -2.31 % |
|
| 2025-02-05 | +2.2 % |
|
| 2025-02-04 | -1.26 % |
|
| 2025-02-03 | -1.21 % |
|
| 2025-01-31 | -1.45 % |
|
| 2025-01-30 | +1.09 % |
- Pfizer (PFE) stock rose by 1.09% due to a positive market sentiment, likely influenced by investor optimism surrounding upcoming economic policies and developments, including the impact of interest rates and fiscal measures that could boost sectors related to healthcare and pharmaceuticals.
- Pfizer (PFE) stock rose by 1.09% recently, despite a downgrade in its price target by Citigroup from $30.00 to $29.00, mainly due to a strong earnings report that exceeded expectations with significant revenue growth, instilling confidence among investors.
- Pfizer (PFE) stock experienced a slight increase of 1.09% despite Citigroup lowering its price target, likely due to a strong quarterly earnings report that exceeded analyst expectations, along with a recently declared dividend increase.
- Pfizer (PFE) stock rose by 1.09% due to positive market sentiment, possibly influenced by broader economic indicators and expectations regarding upcoming policy measures related to spending and tax rebates.
- The article discusses recent Senate hearings regarding Robert F. Kennedy Jr. as a potential head of the Department of Health and Human Services, which have highlighted the influence of pharmaceutical industry donations on lawmakers, amid a backdrop of public discourse on healthcare and vaccine skepticism. Pfizer (PFE) stocks rose by 1.09% likely due to a combination of market dynamics responding to these hearings, investor sentiment regarding potential policy changes, and broader interest in pharmaceutical companies amid ongoing health discussions.
|
| 2025-01-29 | -0.49 % |
|
| 2025-01-28 | -0.41 % |
|
| 2025-01-27 | +2.95 % |
|
| 2025-01-24 | -1.32 % |
|
| 2025-01-23 | +1.65 % |
|
| 2025-01-22 | -2.36 % |
|
| 2025-01-21 | +1.29 % |
- Pfizer (PFE) stock rose 1.29% due to market reactions stemming from a combination of factors, including consolidation trends in the advertising industry that may involve major clients like Pfizer, prompting investor optimism about the company's stability amid broader sector challenges.
- The article discusses the ranking of Canadian universities by CourseCompare, with the University of Toronto being named the best for 2025 due to its strong industry connections and job readiness programs. Pfizer (PFE) stock likely increased because of its collaborations with top universities, including McGill, which enhance its recruitment of skilled graduates and strengthen its industry position.
- Pfizer (PFE) stock rose 1.29% following optimism generated by mergers and acquisitions (M&A) activity in the pharmaceutical industry, including significant deals announced at the JPMorgan Health Care Conference, which may help mitigate the impact of upcoming patent expirations on Pfizer's revenues.
- Pfizer (PFE) stock rose by 1.29% after recent setbacks in clinical trials of competitors' weight-loss drugs opened up the market, creating opportunities for Pfizer's own weight-loss drug candidate, danuglipron, which is still under development.
The rise in Pfizer's stock can be attributed to the disappointing results of competing companies' drugs, which suggests a potential for Pfizer's drug to fill the market gap if successful.
- Ameritas Advisory Services LLC increased its stake in Pfizer Inc. by 3.6%, contributing to a positive sentiment around the stock, which saw a 1.29% rise likely due to increased institutional interest and strong earnings performance reported in October.
|
| 2025-01-17 | -0.72 % |
- Pfizer (PFE) stock experienced a decline of 0.72%, likely due to market reactions to its comparison with smaller companies like Evotec and Citius Pharmaceuticals, which demonstrated stronger potential upside and favorable conditions, indicating a preference for those companies among analysts.
- Pfizer (PFE) stock was down by 0.72% last night, likely influenced by broader market trends and investor behavior reflecting caution and volatility amid changing economic conditions, particularly surrounding inflation metrics and market speculation as noted in the article.
- The article discusses Pam Bondi's disclosure of financial benefits from her involvement in the merger of Digital World Acquisition Corp. and Trump Media, amidst her nomination as attorney general, and does not directly address why Pfizer (PFE) stock fell by 0.72% last night; it could be related to broader market trends, company performance, or investor sentiment unrelated to Bondi or the political events mentioned.
- Pfizer (PFE) stock experienced a decline of -0.72% due to concerns regarding the broader economic impacts of a relentless focus on efficiency, which may risk overshadowing innovation, resilience, and long-term growth within the company and the industry as a whole.
|
| 2025-01-16 | +1.03 % |
- The article discusses a comparison between CannLabs and Celcuity, highlighting that Celcuity has a stronger consensus rating and higher potential upside, as well as significant institutional ownership, which may indicate investor confidence.
Pfizer (PFE) stock may have gone up due to positive investor sentiment stemming from its collaboration with Celcuity on the development and commercialization of the drug candidate Gedatolisib, which targets various cancers, suggesting growth potential for both companies in the biopharmaceutical sector.
- Pfizer (PFE) stock rose by 1.03% last night, likely due to positive analysts' ratings and increased institutional interest in companies collaborating with Pfizer, such as BioRestorative Therapies, which has ongoing research agreements with the pharmaceutical giant.
- The article discusses Pam Bondi's financial disclosures, revealing her significant holdings in Trump's "Truth Social" platform, her earnings after serving as a lobbyist and consultant, and her expected confirmation as attorney general.
Pfizer (PFE) stock may have gone up due to Bondi providing legal services to the company, which could indicate positive sentiment or developments regarding Pfizer in connection with her confirmation and lobbying efforts.
|
| 2025-01-15 | -0.72 % |
|
| 2025-01-14 | -1.46 % |
|
| 2025-01-13 | +0.3 % |
|
| 2025-01-10 | -0.52 % |
|
| 2025-01-08 | -1 % |
- Pfizer (PFE) stock fell by 1.0% amid a volatile market influenced by developments in the bird flu vaccine space and a general downturn in biotech stocks following a drop in Moderna shares, which impacted investor sentiment in the sector.
- Pfizer (PFE) stock decreased by 1.0% amid a volatile market impacted by news about bird flu and the competitive landscape of vaccine development, particularly following Moderna's significant fluctuations and reported losses. The decline in Pfizer's stock may be attributed to overall investor caution regarding vaccine makers as they navigate post-pandemic challenges and shifting market dynamics.
- The article discusses a recent dip in Pfizer (PFE) stock, which fell by 1.0%, while also commenting on the impact of quantum computing on AI stocks and the overall market sentiment driven by recent statements from Nvidia's CEO Jensen Huang.
Pfizer (PFE) stock's decline may be attributed to broader market conditions and investor sentiment, rather than specific issues directly related to the company's performance, as the focus was more on speculative trends in technology and quantum computing.
- Pfizer (PFE) stock experienced a decline of 1.0% amid a broader uptick in vaccine stocks like Moderna, Novavax, and BioNTech, attributed to rising COVID-19 and flu cases, yet Pfizer faced pressure likely due to lower anticipated demand for its vaccines and ongoing competitive challenges from other vaccine developers.
|
| 2025-01-07 | +0.89 % |
|
| 2025-01-06 | +1.13 % |
|
| 2025-01-03 | -0.08 % |
|
| 2025-01-02 | +0.3 % |
- Pfizer (PFE) stock rose 0.3% reportedly due to positive movements in the biotechnology sector, highlighted by recent developments in partnerships and investments with companies like Pieris Pharmaceuticals, which is advancing in its clinical pipeline involving bispecific immuno-oncology programs.
- Pfizer (PFE) stock experienced a 0.3% increase, likely due to its collaboration with Celcuity on the development of the cancer therapy Gedatolisib, which analysts view positively given Celcuity's favorable market position and institutional backing.
- Pfizer (PFE) stock rose by 0.3% due to its partnerships with companies like Protalix BioTherapeutics, which are developing innovative treatments, indicating strong potential for future growth and collaboration in the biopharmaceutical space.
- Pfizer (PFE) stock increased by 0.3% due to favorable comparisons with other medical companies like BioNTech and Alector, highlighting BioNTech's strong revenue, earnings, and lower price-to-earnings ratio, which suggest potential growth in the pharmaceutical sector.
|
| 2024-12-31 | +0.42 % |
|
| 2024-12-30 | -0.75 % |
|
| 2024-12-27 | +0.23 % |
|
| 2024-12-26 | -0.67 % |
|
| 2024-12-24 | +0.11 % |
- The article discusses a podcast featuring Dana Mattioli, a Wall Street Journal reporter, who talks about Amazon's extensive influence and market dominance, highlighting her new book that explores the company's aggressive tactics and its quest for corporate power.
Pfizer (PFE) stock may have gone up by 0.11% due to positive sentiment regarding its product pipeline, market conditions, or investor confidence, but specific reasons are not detailed in the article.
- Pfizer (PFE) stock rose by 0.11% amidst scrutiny of Judge Katharine H. Parker's financial ties to the healthcare industry, including her substantial holdings in Pfizer, which may reflect investor confidence in the company's stability despite ongoing legal controversies in the healthcare sector.
- Pfizer (PFE) stock increased by 0.11% following an upgrade in earnings estimates for FY2025 by Leerink Partners, which raised the forecast from $2.82 to $2.90 per share, reflecting positive investor sentiment after the company reported stronger-than-expected quarterly earnings and revenue.
- The article discusses the potential conflict of interest arising from Magistrate Judge Katharine H. Parker's ties to Pfizer as she oversees pretrial hearings for Luigi Mangione, who is accused of murder, which has raised concerns about the fairness of his trial. Pfizer's stock may have gone up due to investor confidence linked to the company's ongoing legal matters and its healthcare sector connections, coupled with a stable performance within the pharmaceutical industry.
|
| 2024-12-20 | +2.29 % |
|
| 2024-12-19 | -0.46 % |
|
| 2024-12-18 | -2.04 % |
- Pfizer's stock (PFE) fell by 2.04% despite the company affirming its 2024 projections and providing 2025 guidance that aligned with analysts' estimates, likely indicating investor concerns about future growth amid a competitive market landscape.
- Pfizer (PFE) stock declined by 2.04% due to pressure from activist investor Starboard Value LP, which criticized the company for poor shareholder returns and declining demand for its COVID-19 vaccines, prompting Pfizer to consider strategic changes to address these concerns.
- Pfizer (PFE) stock dropped by 2.04% due to a decline in revenues and margins, particularly stemming from reduced demand for Covid-19 vaccines, despite the company announcing cost-cutting measures and a strong growth outlook for other products.
- Pfizer (PFE) stock declined by 2.04% following a report from Leerink Partners that, while indicating the company's 2025 revenue is aligned with Wall Street forecasts, suggests that the outlook is only "marginally encouraging," which may have disappointed investors looking for stronger growth signals.
- Pfizer (PFE) stock fell by 2.04% due to increased competition in the healthcare market, highlighted by recent advancements and positive trial results from competing biotech companies in the oncology space, which may affect investor confidence in Pfizer's market positioning.
|
| 2024-12-17 | +4.67 % |
|
| 2024-12-16 | -1.29 % |
|
| 2024-12-13 | +0.83 % |
|
| 2024-12-12 | +0.55 % |
|
| 2024-12-10 | -2.03 % |
|
| 2024-12-09 | +1.44 % |
|
| 2024-12-06 | +0.12 % |
|
| 2024-12-05 | +1.86 % |
|
| 2024-12-04 | -1.29 % |
- The article discusses the performance of Pfizer (PFE) stock, noting it fell by 1.29%, while highlighting the overall growth and challenges in the biotech sector, particularly for small-cap companies. Pfizer's decline could be attributed to broader market trends affecting biotech stocks, which are increasingly linked to small-cap equities performance and the ongoing turbulence in the industry, including risks related to clinical trial outcomes and funding challenges.
- Pfizer (PFE) stock has declined by 1.29% and is down 7% over the past month due to concerns about its future vaccine sales under new government leadership, declining Covid-19 vaccine sales, and challenges in revenue and margins, alongside scrutiny over its acquisitions and R&D spending.
- Pfizer (PFE) stock experienced a 1.29% decline, possibly due to increased investor focus on the surging cryptocurrency XRP, which has outperformed many established companies including Pfizer, thus drawing attention away from traditional stocks.
|
| 2024-12-03 | -1.01 % |
|
| 2024-12-02 | -1.49 % |
|
| 2024-11-29 | +1.47 % |
|
| 2024-11-27 | +0.23 % |
|
| 2024-11-26 | -1.53 % |
|
| 2024-11-25 | +2.03 % |
- Pfizer (PFE) stock rose 2.03% despite BridgeBio Pharma receiving FDA approval for a competing heart disease treatment, Vyndaqel, which propelled BridgeBio's stock upward.
The increase in Pfizer's stock may be attributed to broader market trends or investor sentiment rather than the approval of the rival drug, as market reactions can be influenced by various factors beyond direct competition.
- The article discusses a Thai tycoon, Boon Vanasin, wanted by police for a $200 million investment scam linked to non-existent medical projects, causing turmoil for his company, Thonburi Healthcare Group, which faced previous scrutiny for misleading claims about acquiring Pfizer vaccines.
Pfizer (PFE) stock may have risen due to positive market sentiment or investor confidence in the company's ongoing developments, though the article does not provide specific reasons for the stock's increase.
- Pfizer Inc. (PFE) stock rose 2.03% last night, as it is perceived as a bargain after significant losses this year and may experience a "January bounce" as tax-motivated selling subsides, particularly since it offers a low price-to-earnings ratio and a high dividend yield.
- Pfizer (PFE) stock increased by 2.03% following the FDA approval of BridgeBio Pharma's Attruby, a new drug for treating a rare heart disease, which prompted analysts to suggest that Pfizer could leverage its marketing to emphasize the mortality benefits of its own competing drug, tafamidis.
- Pfizer (PFE) stock rose by 2.03% due to positive investor sentiment following the company's involvement in health initiatives and its recent study highlighting the economic burden of high blood pressure treatments, which underscores the demand for effective healthcare solutions.
|
| 2024-11-22 | +2.07 % |
|
| 2024-11-21 | +0.76 % |
|
| 2024-11-20 | -0.64 % |
|
| 2024-11-19 | +0.97 % |
|
| 2024-11-18 | +0.24 % |
- The article discusses plans by Donald Trump's co-chair for the Department of Government Efficiency, Vivek Ramaswamy, to drastically reduce the size of the executive branch and eliminate several federal agencies, a move that could potentially lead to government inefficiencies but was described as feasible through executive action.
Pfizer (PFE) stock's recent 0.24% increase is likely attributed to market reactions to the political climate, including shifts in government policy and potential regulatory changes that could affect pharmaceutical companies positively, although the article does not directly discuss Pfizer's stock.
- The article discusses the tension between Elon Musk and Donald Trump's team regarding key economic issues, particularly tariffs, as Musk attempts to influence Trump's administration while facing resistance from other advisors. Pfizer (PFE) stock's 0.24% increase may be attributed to positive investor sentiment driven by ongoing developments in healthcare, robust earnings forecasts, or favorable news regarding potential drug approvals and market performance.
- The article discusses the appointment of FCC Commissioner Brendan Carr by Donald Trump and the broader implications of Trump's plans for his next administration, including potential cuts to government agencies and heightened scrutiny of nonprofit organizations. The Pfizer (PFE) stock may have gone up due to positive investor sentiment tied to broader market movements or potential favorable news regarding the company's developments, although this is not explicitly detailed in the article.
- Pfizer's (PFE) stock rose by 0.24% likely due to positive developments related to Vaccinex, Inc.'s drug candidate pepinemab, which shows promise in slowing cognitive decline in Alzheimer's disease and enhancing immune response in certain cancers, indicating potential partnerships or collaboration opportunities in the biopharmaceutical sector.
|
| 2024-11-15 | -4.69 % |
|
| 2024-11-14 | -2.62 % |
|
| 2024-11-12 | -0.19 % |
|
| 2024-11-08 | -2.69 % |
|
| 2024-11-07 | +0.37 % |
|
| 2024-11-06 | -2.25 % |
|
